Pfizer Inc (PFE) 30.96 $PFE
Genentech Alzheimer's drug misses goals in studies
By MARILYNN MARCHIONE - AP - Wed Jul 16, 5:57PM CDT
An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose.
Pfizer Set to Possibly Pullback After Yesterday's Rally of 1.81%
Comtex SmarTrend(R) - Wed Jul 16, 4:21PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $30.37 to a high of $30.97. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $30.62 on volume of 32.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Most active New York Stock Exchange-traded stocks
AP - Wed Jul 16, 1:54PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Wed Jul 16, 1:54PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Why Pfizer (PFE) Stock Is Up Today
at The Street - Wed Jul 16, 11:58AM CDT
Pfizer (PFE) rose Wednesday after the pharmaceutical giant said its drug BeneFIX reached its primary endpoint in a Phase 3 trial.
Early Glance: Pharmaceuticals companies
AP - Wed Jul 16, 10:11AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
#FOGO? - New Survey Reveals 87% of Americans have a Fear of Getting Old (FOGO) - Results Show Top Fear is Decline in Physical Ability(1)
Business Wire - Wed Jul 16, 9:00AM CDT
--New social study finds 4.2 million tweets a year on aging; topic of health grew 48% in 2014 over 2013(2)
Pfizer to Acquire InnoPharma, Inc.
Business Wire - Wed Jul 16, 8:26AM CDT
--Portfolio of 10 Approved Products and Pipeline of More Than 30 Products in Development; 19 Pending Approval with the United States Food and Drug Administration
Top Stocks to Watch Today: St. Jude Medical, Abbott Laboratories, Eli Lilly, Pfizer
Leo Sun, The Motley Fool - Motley Fool - Wed Jul 16, 7:57AM CDT
Let's take a quick look at four stocks -- St. Jude Medical , Abbott Laboratories , Eli Lilly , and Pfizer -- which could loom large in health care headlines this Wednesday morning. St. Jude Medical beats estimates for the second quarter ...
Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements
PR Newswire - Wed Jul 16, 7:15AM CDT
Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).
Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX(R)) Once-Weekly Prophylaxis For Hemophilia B
Business Wire - Wed Jul 16, 6:00AM CDT
Pfizer Inc. (NYSE FE) today announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX(R) Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX (100 IU/Kg) showed a statistically significant reduction in the annualized bleeding rate (ABR) (P < 0.0001) relative to on-demand treatment with BeneFIX.
With Tips From Pfizer, AbbVie Lands the Biggest Pharma Deal of the Year: StockTwits
at The Street - Tue Jul 15, 7:49PM CDT
AbbVie has learned some of the lessons of the M&A business, offering a huge premium for Shire, but for a very good reason.
Why Is Wall Street Bullish on These 3 Stocks?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
Rising institutional ownership combined with a low short interest are probably a couple of good signs that Wall Street thinks a stock has strong upside potential. Even so, it's not always entirely clear why the Street is bullish on a particular...
Why TheStreet Ratings Team Rates Pfizer (PFE) Stock a 'Buy'
at The Street - Tue Jul 15, 2:43PM CDT
TheStreet Ratings team reiterates its "buy" rating on Pfizer (PFE) with a ratings score of B+.
Johnson & Johnson Beats on Q2 Earnings, Ups View Again - Analyst Blog
Abhijit Ghosh - Zacks Investment Research - Tue Jul 15, 9:55AM CDT
J&J's pharma segment put in a strong performance again with recently launched hepatitis C treatment Olysio boosting sales.
Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
M2 - Tue Jul 15, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mstbv/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA. Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA. The report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Competitive Analysis of Marketed Products - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Types - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/5m..._pva_drugs
Genentech Alzheimer's drug misses goals in studies
By MARILYNN MARCHIONE - AP - Wed Jul 16, 5:57PM CDT
An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose.
Pfizer Set to Possibly Pullback After Yesterday's Rally of 1.81%
Comtex SmarTrend(R) - Wed Jul 16, 4:21PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $30.37 to a high of $30.97. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $30.62 on volume of 32.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. Most active New York Stock Exchange-traded stocks
AP - Wed Jul 16, 1:54PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Wed Jul 16, 1:54PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Why Pfizer (PFE) Stock Is Up Today
at The Street - Wed Jul 16, 11:58AM CDT
Pfizer (PFE) rose Wednesday after the pharmaceutical giant said its drug BeneFIX reached its primary endpoint in a Phase 3 trial.
Early Glance: Pharmaceuticals companies
AP - Wed Jul 16, 10:11AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
#FOGO? - New Survey Reveals 87% of Americans have a Fear of Getting Old (FOGO) - Results Show Top Fear is Decline in Physical Ability(1)
Business Wire - Wed Jul 16, 9:00AM CDT
--New social study finds 4.2 million tweets a year on aging; topic of health grew 48% in 2014 over 2013(2)
Pfizer to Acquire InnoPharma, Inc.
Business Wire - Wed Jul 16, 8:26AM CDT
--Portfolio of 10 Approved Products and Pipeline of More Than 30 Products in Development; 19 Pending Approval with the United States Food and Drug Administration
Top Stocks to Watch Today: St. Jude Medical, Abbott Laboratories, Eli Lilly, Pfizer
Leo Sun, The Motley Fool - Motley Fool - Wed Jul 16, 7:57AM CDT
Let's take a quick look at four stocks -- St. Jude Medical , Abbott Laboratories , Eli Lilly , and Pfizer -- which could loom large in health care headlines this Wednesday morning. St. Jude Medical beats estimates for the second quarter ...
Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements
PR Newswire - Wed Jul 16, 7:15AM CDT
Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).
Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX(R)) Once-Weekly Prophylaxis For Hemophilia B
Business Wire - Wed Jul 16, 6:00AM CDT
Pfizer Inc. (NYSE
FE) today announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX(R) Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX (100 IU/Kg) showed a statistically significant reduction in the annualized bleeding rate (ABR) (P < 0.0001) relative to on-demand treatment with BeneFIX. With Tips From Pfizer, AbbVie Lands the Biggest Pharma Deal of the Year: StockTwits
at The Street - Tue Jul 15, 7:49PM CDT
AbbVie has learned some of the lessons of the M&A business, offering a huge premium for Shire, but for a very good reason.
Why Is Wall Street Bullish on These 3 Stocks?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
Rising institutional ownership combined with a low short interest are probably a couple of good signs that Wall Street thinks a stock has strong upside potential. Even so, it's not always entirely clear why the Street is bullish on a particular...
Why TheStreet Ratings Team Rates Pfizer (PFE) Stock a 'Buy'
at The Street - Tue Jul 15, 2:43PM CDT
TheStreet Ratings team reiterates its "buy" rating on Pfizer (PFE) with a ratings score of B+.
Johnson & Johnson Beats on Q2 Earnings, Ups View Again - Analyst Blog
Abhijit Ghosh - Zacks Investment Research - Tue Jul 15, 9:55AM CDT
J&J's pharma segment put in a strong performance again with recently launched hepatitis C treatment Olysio boosting sales.
Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
M2 - Tue Jul 15, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mstbv/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA. Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA. The report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Competitive Analysis of Marketed Products - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Types - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/5m..._pva_drugs
